The Diabetes Quiz Game: Optimizing Type 2 Diabetes Management With GLP-1 Receptor Agonists

In this recorded presentation of an independent CCO diabetes symposium, Richard Pratley, MD, John Russell, MD, and Neil Skolnik, MD, review best practices regarding the use of GLP-1 receptor agonists for the optimal management of A1C levels in patients with type 2 diabetes.
John Russell, MD
Program Director
Richard E. Pratley, MD
John Russell, MD
Neil S. Skolnik, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: October 28, 2015 Expiration: October 27, 2016

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply ADA/AACE guidelines to the management of patients with type 2 diabetes
  • Design pharmacologic strategies that optimize the use of GLP-1 receptor agonist therapy in the management of patients with type 2 diabetes
  • Apply new and emerging data regarding combining injectable therapies in appropriate patients to improve glycemic control and patient outcomes in type 2 diabetes
  • Apply glucose-lowering strategies with attention to individual patient factors that affect treatment outcomes and safety

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

John Russell, MD

Clinical Professor
Department of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel Medical College
Philadelphia, Pennsylvania
Program Director
Family Medicine Residency Program
Abington Hospital
Abington, Pennsylvania

John Russell, MD, has disclosed that he has received consulting fees from Galderma and fees for non-CME/CE services from Sanofi Pasteur.

Faculty

Richard E. Pratley, MD

Medical Director of Education and Research
Florida Hospital Diabetes Institute
Senior Scientist
Translational Research Institute for Metabolism and Diabetes
Adjunct Professor
Sanford Burnham Prebys Medical Discovery Institute at Lake Nona
Orlando, Florida

Richard E. Pratley, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hanmi, Merck, Novo Nordisk, and Takeda; fees for non-CME/CE services from AstraZeneca and Novo Nordisk; and funds for research support from Gilead Sciences, Eli Lilly & Co, Merck, Novo Nordisk, sanofi-aventis, and Takeda.
John Russell, MD

Clinical Professor
Department of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel Medical College
Philadelphia, Pennsylvania
Program Director
Family Medicine Residency Program
Abington Hospital
Abington, Pennsylvania

John Russell, MD, has disclosed that he has received consulting fees from Galderma and fees for non-CME/CE services from Sanofi Pasteur.
Neil S. Skolnik, MD

Associate Director
Family Medicine Residency Program
Abington Hospital
Abington, Pennsylvania
Professor, Family and Community Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania

Neil S. Skolnik, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, sanofi-aventis, and Teva; and fees for non-CME/CE services and funds for research support from AstraZeneca.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.
Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for family physicians and other primary care providers who manage patients with type 2 diabetes.

Goal

The goal of this activity is to improve family physicians’ knowledge and competence related to the safe and appropriate use of GLP-1 receptor agonists in the management of patients with type 2 diabetes in order to advance patient outcomes and improve glycemic control.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2015, through October 27, 2016:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CME: Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM

Veronica K. Piziak, MD, PhD, FACP
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: January 11, 2019 Expiration: January 10, 2020

Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM

Veronica K. Piziak, MD, PhD, FACP
Program Director
Released: December 10, 2018

CME: T2DM and CV risk management. Guillermo Umpierrez on choosing A1C and using guidelines/algorithms for metformin, SUs, TZDs, DPP-4s, SGLT2s

Guillermo E. Umpierrez, MD, CDE Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: December 5, 2018 Expiration: December 4, 2019

Drs. Jacobson and Newsome summarize the most important NAFLD/NASH data from AASLD 2018: Noninvasive screening, clinical outcomes, emerging treatments.

Ira M. Jacobson, MD Philip N. Newsome, PhD, FRCPE Released: December 3, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?